The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price cut by equities research analysts at The Goldman Sachs Group from $41.00 to $36.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 87.99% from the stock’s current price.

Several other analysts have also issued reports on the stock. William Blair began coverage on shares of Viridian Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Wedbush reduced their target price on shares of Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a research note on Tuesday. Truist Financial decreased their target price on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Finally, UBS Group initiated coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Stock Down 2.1%

Shares of VRDN stock opened at $19.15 on Tuesday. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a quick ratio of 12.65, a current ratio of 12.65 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.96 billion, a PE ratio of -5.82 and a beta of 1.16. The stock has a 50 day moving average of $28.90 and a 200-day moving average of $27.83.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, equities analysts predict that Viridian Therapeutics will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its holdings in shares of Viridian Therapeutics by 0.8% during the 4th quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock worth $1,369,000 after acquiring an additional 356 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Viridian Therapeutics by 0.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after acquiring an additional 380 shares during the period. US Bancorp DE raised its position in Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after purchasing an additional 876 shares in the last quarter. Finally, Virtus Investment Advisers LLC lifted its stake in Viridian Therapeutics by 13.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 8,233 shares of the company’s stock worth $256,000 after purchasing an additional 971 shares during the period.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Company reported positive topline results from the Elegrobart Phase 3 REVEAL‑1 trial in active thyroid eye disease — the clinical readout is a fundamental positive for long‑term drug value and commercial potential. Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and set a $22 target while revising Q1–Q4 and FY2026 EPS estimates (small mix of raises and cuts) — shows continued analyst support but revised modeling reflects higher near‑term costs/assumptions. HC Wainwright estimate and rating note
• Neutral Sentiment: Recent intraday swings included a sharp bounce the prior session (Zacks noted a 5.6% jump on higher‑than‑average volume), highlighting that VRDN is trading on headline events and momentum as much as fundamentals. Viridian Therapeutics (VRDN) Soars 5.6%
• Negative Sentiment: Shares plunged pre‑market on headlines that followed the Phase 3 disclosure (market reaction suggests investors were disappointed by details beyond topline, or that expectations were higher), triggering heavy selling and volatility. VRDN stock plummeted 41% pre-market today
• Negative Sentiment: Multiple firms trimmed price targets (Goldman Sachs to $36, Wells Fargo to $20 with an equal‑weight, Wedbush to $37, HC Wainwright down to $22) — these cuts signal reduced near‑term upside in sell‑side models and likely contributed to downward pressure. Broker price target updates
• Negative Sentiment: Several news outlets highlighted that shares fell despite the positive topline, suggesting investor concerns about safety details, subgroup results, magnitude of benefit, or commercial assumptions — expect continued headline‑driven trading until full data and guidance are clarified. Viridian Therapeutics stock tumbles despite trial success

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.